Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 1.8M | 6.3% |
| Gross Profit | -38M | 0.5% |
| Cost of Revenue | 40M | 0.8% |
| Operating expense | 65M | 15% |
| Net Income | -65M | 21.3% |
| EBITDA | -64M | 24.7% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 321M | 14% |
| Total Liabilities | 143M | 6.9% |
| Total Equity | 179M | 25.6% |
| Shares Outstanding | 361M | 16.3% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -54M | 10.5% |
| Cash from investing | 53M | 533.9% |
| Cash from financing | -920,000 | 6442.9% |
EPS
Financial Highlights for Lexicon Pharmaceuticals in Q3 '24
Lexicon Pharmaceuticals reported a revenue of 1.8M, which is a 6.3% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -38M, marking a -0.5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 40M, a 0.8% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 65M, showing a 15% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -65M, showing a -21.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -64M, showing a -24.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Lexicon Pharmaceuticals faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
